Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Bruno Paiva et al.|Blood Advances|2021Cited by 25
A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristicsRicardo Sánchez, Joaquín Martínez‐López, Jordi Ribera et al.|Blood Cancer Journal|2020Cited by 23
Translocation (3;8)(q27;q24) in two cases of triple hit lymphomaCristina Motlló, Fuensanta Millá, Javier Grau et al.|Cancer Genetics and Cytogenetics|2010Cited by 21
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Rebeca Rodriguez Veiga et al.|Blood|2023Cited by 15
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 13